Foghorn Therapeutics (FHTX) Insider Trading & Ownership $4.37 -0.04 (-0.91%) As of 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Foghorn Therapeutics (NASDAQ:FHTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage9.07%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$367,705.93 Get FHTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Foghorn Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address FHTX Insider Buying and Selling by Quarter Foghorn Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/23/2024Carlos CostainsiderSell857$10.17$8,715.69 9/20/2024Carlos CostainsiderSell35,756$10.04$358,990.24 (Data available from 1/1/2013 forward) FHTX Insider Trading Activity - Frequently Asked Questions Who is on Foghorn Therapeutics's Insider Roster? The list of insiders at Foghorn Therapeutics includes Carlos Costa, and Samuel Agresta. Learn more on insiders at FHTX. What percentage of Foghorn Therapeutics stock is owned by insiders? 9.07% of Foghorn Therapeutics stock is owned by insiders. Learn more on FHTX's insider holdings. Which Foghorn Therapeutics insiders have been selling company stock? The following insiders have sold FHTX shares in the last 24 months: Carlos Costa ($367,705.93), and Samuel Agresta ($2,568,200.25). How much insider selling is happening at Foghorn Therapeutics? Insiders have sold a total of 347,910 Foghorn Therapeutics shares in the last 24 months for a total of $2,935,906.18 sold. Foghorn Therapeutics Key ExecutivesMr. Adrian H. B. Gottschalk (Age 48)President, CEO & Director Compensation: $784.65kDr. Steven F. Bellon Ph.D. (Age 59)Chief Scientific Officer Compensation: $572.6kDr. Alfonso Quintas Cardama M.D. (Age 53)Chief Medical Officer Compensation: $300.16kDr. Gerald R. Crabtree M.d.Founder & Member of Scientific Advisory BoardMr. Kristian Humer M.B.A. (Age 48)Chief Financial Officer Ms. Karin HellsvikVP, Corporate Affairs & Investor RelationsMr. Michael J. LaCascia (Age 59)Chief Legal Officer Compensation: $565.5kMr. Saurabh Sewak Ph.D.Vice President of Corporate DevelopmentMr. Carlos Costa (Age 51)Chief People Officer 2 recent tradesMs. Fanny Cavalie (Age 46)Chief Strategy & Business Operations Officer More Insider Trading Tools from MarketBeat Related Companies Zymeworks Insider Trading Adaptive Biotechnologies Insider Trading Gyre Therapeutics Insider Trading Poseida Therapeutics Insider Trading Nuvation Bio Insider Trading Anavex Life Sciences Insider Trading AbCellera Biologics Insider Trading ArriVent BioPharma Insider Trading Cogent Biosciences Insider Trading Phibro Animal Health Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (NASDAQ:FHTX) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredThe Stock I’m Calling My #1 of the DecadeThe stock I reveal right here is my #1 stock of the decade. In fact, it might be my favorite stock ever. ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
